GetTopicDetailResponse(id=248e1243051f, topicName=氘代衍生物, introduction=, content=EGFR突變型非小細胞肺癌 奧希替尼 氘代衍生物, image=null, comments=0, allHits=323, url=null, type=0, isShow=1, status=1, isAdmin=null, adminId=5395722, adminEncryptionId=cade5395722, adminName=梅斯管理員, createdBy=cade5395722, createdName=梅斯管理員, createdAvatar=, createdTime=Mon Feb 17 09:56:22 CST 2025, time=2025-02-17, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=501560, tagList=[TagDto(tagId=501560, tagName=氘代衍生物)], ipAttribution=陜西省, topicAdmin=0, lengthMark=0)
[GetTopicListResponse(id=2252304, encodeId=629d225230477, content=<a href='/topic/show?id=b94f659596' target=_blank style='color:#2F92EE;'>#EGFR突變型非小細胞肺癌#</a> <a href='/topic/show?id=b0054454337' target=_blank style='color:#2F92EE;'>#奧希替尼#</a> <a href='/topic/show?id=248e1243051f' target=_blank style='color:#2F92EE;'>#氘代衍生物#</a>, objectTitle=J Thorac Oncol：氘代奧希替尼衍生物（TY-9591）在晚期EGFR突變非小細胞肺癌中的安全性、藥代動力學(xué)和療效：一項1期劑量遞增和劑量擴展研究, objectType=article, longId=863606, objectId=cb968636063b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240618/1718704154726_92910.png, objectUrl=/article/show_article.do?id=cb968636063b, replyNumber=0, likeNumber=47, createdTime=2025-02-17, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陜西省, moduleDTOList=[ModuleDTO(moduleId=cb968636063b, moduleTitle=J Thorac Oncol：氘代奧希替尼衍生物（TY-9591）在晚期EGFR突變非小細胞肺癌中的安全性、藥代動力學(xué)和療效：一項1期劑量遞增和劑量擴展研究, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=cb968636063b)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯管理員
2025-02-17發(fā)表于陜西省
